Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lorlatinib in LTK fusion-positive NSCLC (3L study)
jRCT2031220600Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Objective Response Rate. Started Feb 2022; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220600.